Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It
NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It
NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It
Submitted by
admin
on February 3, 2013 - 11:35am
Source:
Y Charts
News Tags:
Gattex
NPS Pharmaceuticals
short bowel syndrome
Headline:
NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It
Do Not Allow Advertisers to Use My Personal information
